Education
About Us
Working with TipRanks
Follow Us
Soligenix Inc (SNGX)
:SNGX
Top Page
Soligenix
(NASDAQ:SNGX)
37Underperform
Soligenix (SNGX) vs. S&P 500 (SPY)
Market Cap
$5.82M
Dividend YieldN/A
Average Volume (3M)30.93K
Price to Earnings (P/E)―
Beta (1Y)0.59
Revenue Growth-100.00%
EPS Growth76.13%
CountryUS
Employees13
SectorHealthcare
Sector Strength78
IndustryBiotechnology
Share Statistics
EPS (TTM)-7.80
Shares Outstanding2,509,499
10 Day Avg. Volume21,568
30 Day Avg. Volume30,927
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)15.99
Price to Cash Flow (P/CF)-0.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Soligenix Business Overview & Revenue Model
Company DescriptionSoligenix, Inc. (SNGX) is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates in two segments: BioTherapeutics and Public Health Solutions. The BioTherapeutics segment is dedicated to developing products for orphan diseases and areas of unmet medical need, including proprietary formulations of oral mucositis, cutaneous T-cell lymphoma, and pediatric Crohn's disease. The Public Health Solutions segment aims to develop vaccines and therapeutics for military and civilian applications in areas such as ricin toxin, melioidosis, Ebola virus, and radiation exposure.
How the Company Makes MoneySoligenix generates revenue primarily through strategic partnerships, government contracts, and grants. In its BioTherapeutics segment, the company seeks to commercialize its proprietary drug candidates by partnering with larger pharmaceutical companies that have the resources to support late-stage clinical trials and distribution. These partnerships often involve upfront payments, milestone payments, and royalties on product sales. In the Public Health Solutions segment, Soligenix benefits from government funding and contracts, particularly from agencies focused on biodefense and public health initiatives. This funding supports the development of vaccines and therapeutics, providing a significant revenue stream while advancing their product pipeline.
Soligenix Financial Statement Overview
Summary
Soligenix faces significant financial challenges across its income statement, balance sheet, and cash flow statement. Consistent losses, high leverage, and negative cash flow trends are evident. There are some signs of improvement in equity and liquidity, but overall, the financial health remains weak.Income Statement
Soligenix's income statement reflects significant challenges, with consistently negative EBIT and net income indicating ongoing operating losses. Revenue growth is volatile, with a recent decline in TTM revenue compared to previous annual figures. Margins remain under pressure, as evidenced by negative gross and net profit margins, suggesting profitability challenges.30
Negative
Balance Sheet
The balance sheet reveals a strained financial position, with a high debt-to-equity ratio and negative equity in past periods, though equity has improved recently. The company's equity ratio has improved, but overall leverage remains high, posing financial risk. Cash reserves are solid relative to liabilities, providing some liquidity cushion.40
Negative
Cash Flow
Cash flow analysis shows negative free cash flow and operating cash flow, indicating challenges in generating cash from operations. Recent improvements in financing activities have bolstered cash reserves, but the reliance on external financing is a concern. The operating cash flow to net income ratio highlights ongoing cash generation issues.35
Negative
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 364.18K | 839.36K | 948.91K | 824.27K | 2.36M | 4.63M | Gross Profit |
| 20.09K | 97.31K | 398.09K | 95.63K | 538.50K | 1.06M | EBIT |
| -8.23M | -7.70M | -14.11M | -12.97M | -18.49M | -10.11M | EBITDA |
| -7.84M | -7.85M | -14.11M | -12.23M | -18.23M | -9.36M | Net Income Common Stockholders |
| -7.10M | -6.14M | -13.80M | -12.55M | -17.69M | -9.36M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 8.98M | 8.45M | 13.36M | 26.04M | 18.68M | 5.42M | Total Assets |
| 10.49M | 9.80M | 14.28M | 26.87M | 19.89M | 7.78M | Total Debt |
| 0.00 | 3.49M | 10.24M | 9.96M | 10.51M | 127.22K | Net Debt |
| -8.98M | -4.95M | -3.12M | -16.08M | -8.17M | -5.29M | Total Liabilities |
| 4.21M | 7.27M | 16.75M | 16.15M | 16.15M | 6.32M | Stockholders Equity |
| 6.28M | 2.52M | -2.47M | 10.72M | 3.74M | 1.46M |
| Cash Flow | Free Cash Flow | ||||
| -8.00M | -8.60M | -12.66M | -11.75M | -11.46M | -7.54M | Operating Cash Flow |
| -8.00M | -8.60M | -12.65M | -11.74M | -11.45M | -7.51M | Investing Cash Flow |
| -1.20M | 0.00 | -13.07K | -11.79K | -7.15K | -24.71K | Financing Cash Flow |
| 7.47M | 3.66M | 76.82K | 19.06M | 24.68M | 4.01M |
Soligenix Technical Analysis
Negative
2.32
Price Trends
2.49
Negative
2.96
Negative
3.56
Negative
Market Momentum
-0.05
Negative
45.88
Neutral
64.44
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SNGX, the sentiment is Negative. The current price of 2.32 is below the 20-day moving average (MA) of 2.33, below the 50-day MA of 2.49, and below the 200-day MA of 3.56, indicating a bearish trend. The MACD of -0.05 indicates Negative momentum. The RSI at 45.88 is Neutral, neither overbought nor oversold. The STOCH value of 64.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SNGX.
Soligenix Risk Analysis
Soligenix disclosed 47 risk factors in its most recent earnings report. Soligenix reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Soligenix Peers Comparison
Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $54.83M | ― | -118.50% | ― | 1.80% | 33.06% | |
49 Neutral | $6.90B | 0.02 | -54.05% | 2.46% | 24.91% | -3.14% | |
37 Underperform | $5.82M | ― | -139.80% | ― | -100.00% | 76.13% | |
32 Underperform | $9.35M | ― | 234.90% | ― | ― | 46.67% | |
32 Underperform | $25.12M | ― | -227.76% | ― | ― | 30.96% | |
20 Underperform | $1.28M | ― | 197.20% | ― | ― | ― |
* Healthcare Sector Average
Performance Comparison
SNGX
Soligenix
2.30
-7.89
-77.43%
CVM
Cel-Sci
0.30
-1.81
-85.78%
ADXS
Advaxis
0.03
-0.64
-95.52%
BCLI
Brainstorm Cell Therapeutics
1.56
-3.37
-68.36%
CTSO
Cytosorbents
1.07
0.10
10.31%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.